2023.01-至今???? ?中國(guó)科學(xué)院廣州生物醫(yī)藥與健康研究院? ?副研究員

2020.07-2022.06 ???中國(guó)科學(xué)院廣州生物醫(yī)藥與健康研究院 ??博士后

2017.09-2020.06 ???中國(guó)科學(xué)院廣州生物醫(yī)藥與健康研究院? ?博士 ?

1、計(jì)算機(jī)輔助藥物設(shè)計(jì)

2、藥物化學(xué)

1. 國(guó)家自然科學(xué)基金青年基金，22107102，2022.01-2024.12，30萬(wàn)，主持

2. 廣東省區(qū)域聯(lián)合基金青年基金，2020A1515110793，2020.10-2023.09，10萬(wàn)，主持

3. 廣東省自然科學(xué)基金面上項(xiàng)目，2023A1515010418，2023.01-2025.12，10萬(wàn)，主持

4. 中國(guó)科學(xué)院青年創(chuàng)新促進(jìn)會(huì)，2023.01-2026.12，80萬(wàn)，主持

2018年度廣東省自然科學(xué)獎(jiǎng)二等獎(jiǎng)（第八完成人）

2020年中國(guó)科學(xué)院大學(xué)優(yōu)秀畢業(yè)生

2020年北京市普通高等學(xué)校優(yōu)秀畢業(yè)生

[1]? Wu, X. S^#.; Shen, H^#.; Zhang, Y^#.; Wang, C.; Li, Q.; Zhang, C.; Zhuang, X. X.; Li, C. C.; Shi, Y. D.; Xing, Y. L.; Xiang, Q. P.; Xu, J. X.; Wu, D. H.; Liu, J. S.; Xu, Y*. Discovery and characterization of benzimidazole derivative XY123 as a potent, selective, and orally available RORγ inverse agonist. J Med Chem 2021, 64, 8775-8797.

[2]?? Wu, X. S.; Zhang, Y.; Xu, Y*. Discovery of the first low nanomolar liver receptor homolog-1 (LRH-1) agonist. J Med Chem 2019, 62, 11019-11021.

[3]?? Zhang, Y^#.; Wu, X. S^#.; Xue, X. Q^#.; Li, C. C.; Wang, J. J.; Wang, R.; Zhang, C.; Wang, C.; Shi, Y. D.; Zou, L. J.; Li, Q.; Huang, Z. H.; Hao, X. J.; Loomes, K.; Wu, D. H.; Chen, H. W.; Xu, J. X.; Xu, Y*. Discovery and characterization of XY101, a potent, selective, and orally bioavailable RORγ inverse agonist for treatment of castration-resistant prostate cancer. J Med Chem 2019, 62, 4716-4730.

[4]?? Wu, X. S^#.; Wang, R^#.; Xing, Y. L^#.; Xue, X, Q.; Zhang, Y.; Lu, Y. Z.; Song, Y.; Luo, X. Y.; Wu, C.; Zhou, Y. L.; Jiang, J. Q*.; Xu, Y*. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin- 2(1H)-ones as RORc inverse agonists. Acta Pharmacol Sin 2016, 37, 1516-1524.

[5]?? Li, Q^#.; Yao, B. Q^#.; Zhao, S. T.; Lu, Z.; Zhang, Y.; Xiang, Q. P.; Wu, X. S.; Yu, H. N.; Zhang, C.; Li, J. H.; Zhuang, X. X.; Wu, D. H.; Li, Y*.; Xu, Y*. Discovery of a highly selective and H435R-sensitive thyroid hormone receptor β agonist. J Med Chem 2022, 65, 7193-7211.

[6]?? Xiang, Q. P^#.; Wang, C^#.; Wu, T. B^#.; Zhang, C.; Hu, Q. Q.; Luo, G. L.; Hu, J. K.; Zhuang, X. X.; Zou, L. J.; Shen, H.; Wu, X. S.; Zhang, Y.; Kong, X. Q.; Liu, J. S.; Xu, Y*. Design, synthesis, and biological evaluation of 1-(indolizin-3-yl)ethan-1-ones as CBP bromodomain inhibitors for the treatment of prostate cancer. J Med Chem 2022, 65, 785-810.

[7]? Li, J. H^#.; Zhang, C^#.; Xu, H. R.; Wang, C.; Dong, R. B.; Shen, H.; Zhuang, X. X.; Chen, X. S.; Li, Q.; Lu, J. B.; Zhang, M. F.; Wu, X. S.; Loomes, K. M.; Zhou, Y. L.; Zhang, Y.; Liu, J. S.; Xu, Y*. Structure-based discovery and optimization of furo[3,2-c]pyridin-4(5H)-one derivatives as potent and second bromodomain (BD2)-selective bromo and extra terminal domain (BET) inhibitors. J Med Chem 2022, 65, 5760-5799.

[8]?? Zhang, M. F^#*.; Luo, X. Y^#.; Zhang, C.; Wang, C.; Wu, X. S.; Xiang, Q. P.; Xu, Y*.; Zhang, Y*. Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia. Acta Pharmacol Sin 2022, 0, 1-14.

[9]?? Xu, H. R.; Luo, G. L.; Wu, T. B.; Hu, J. K.; Wang, C.; Wu, X. S.; Zhang, Y*.; Xu, Y*.; Xiang, Q. P*. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain. Biochem Biophys Res Commun 2022, 623, 17-22.

[10] Hu, Q. Q.; Wang, C.; Xiang, Q. P.; Wang, R.; Zhang, C.; Zhang, M. F.; Xue, X. Q.; Luo, G. L.; Liu, X. M.; Wu, X. S.; Zhang, Y.; Wu, D. H.; Xu Y*. Discovery and optimization of novel N-benzyl-3,6-dimethyl benzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities. Bioorg Chem 2020, 94, 103424.

[11] Zhang, M. F^#.; Zhang, Y^#.; Song, M^#.; Xue, X. Q.; Wang, J. J.; Wang, C.; Zhang, C.; Li, C. C.; Xiang, Q. P.; Zou, L. J.; Wu, X. S.; Wu, C.; Dong, B. J.; Xue, W.; Zhou, Y. L.; Chen, H. W.; Wu, D. H.; Ding, K.; Xu Y*. Structure-based discovery and optimization of benzo[d]isoxazole derivatives as potent and selective BET inhibitors for potential treatment of castration-resistant prostate cancer (CRPC). J Med Chem 2018, 61, 3037-3058.

[12] Song, Y.; Xue, X. Q.; Wu, X. S.; Wang, R.; Xing, Y. L.; Yan, W. Q.; Zhou, Y. L.; Qian, C. N.; Zhang, Y*.; Xu Y*. Identification of N-phenyl-2-(N-phenyl phenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation. Eur J Med Chem 2016, 116, 13-26.

?